

## MetaboGen has reached a new crucial milestone in its development of novel probiotic products

MetaboGen aims at developing next generation probiotic products focusing on metabolic conditions with special emphasis on diabetes and related diseases. The company has now received approval from the Ethics Committee to start a new clinical study.

After obtaining positive results in the initial clinical study with the strains *Faecalibacterium prausnitzii* (DSM 32379) and *Desulfovibrio piger* (DSM 32187), MetaboGen has now received approval from the Ethics Committee to proceed into its next clinical study, targeting a pre-diabetic population.

"We are really looking forward to the outcome of our next clinical study. In parallel we are working on the optimization of our production processes to prepare for commercial scale. The bacteria we work with are very sensitive to oxygen, so we have developed and patented a unique production technology which helps us overcome this challenge. We are very excited about these next steps and look forward to launching our first product," says Sara Malcus, Managing Director of MetaboGen.

**For additional information please contact** Sara Malcus, Managing Director of MetaboGen: +46 705 82 32 22 Isabelle Ducellier, CEO of BioGaia: +46 8 555 293 00

Latest press releases from BioGaia

04.02.2021	BioGaia AB – Year-end report 2020
03.02.2021	BioGaia revises dividend policy
27.01.2021	BioGaia invests in Sweden – launches its entire adult health portfolio

BioGaia is a Swedish world-leading probiotic company that has been at the forefront of microbiome research for more than 30 years. BioGaia develops, markets and sells probiotic products with documented health benefits. To date, over 200 articles on clinical trials with BioGaia's probiotic strains have been published. The products are sold by nutrition and pharmaceutical companies in more than 100 countries. The class B share of the Parent Company BioGaia AB is quoted on the Mid Cap segment of Nasdaq Stockholm. <u>biogaia.com</u>